Follow-up of a sebaceous carcinoma of the eyelids: A case report.
[Follow-up of a sebaceous carcinoma of the eyelids: A case report]. J Fr Ophtalmol. 2019 Jun 13;: Authors: El Moize Z, Abdallah E, Benazzou S, Amazouzi A, Cherkaoui O PMID: 31204087 [PubMed - as supplied by publisher]
ConclusionReal-time indocyanine green fluorescence imaging may be particularly helpful for delineating the anatomical surgical plane and determining the appropriate division point of the hepatic duct during laparoscopic living donor hepatectomy.
ConclusionThe novel approach for transthoracic hepatectomy was safe and feasible for lesions of segment VIII in selected patients with cirrhosis,8 which was associated with reduced blood loss and a safe surgical margin.
This study investigates the role of LAMC2 in epithelial-mesenchymal transition (EMT) and angiogenesis in CCA and explores the underlying mechanism(s) . Differentially expressed genes related to CCA were initially screened using a microarray analysis, and the interaction between LAMC2 and the EGFR signaling pathway was identified.
Abstract Endometrial tuberculosis is a rare diagnosis in the postmenopausal period, and it can mimic a carcinoma. The present article describes the case of a 54-year-old female patient with weight loss, abdominal pain, and ascites. An ultrasonography showed endometrial thickening, and a video hysteroscopy revealed a uterine cavity with formations with cotton aspect covering the entire endometrial surface and the tubal ostia. An anatomopathological evaluation diagnosed endometrial tuberculosis. The treatment was with a standardized therapeutic scheme (ethambutol, isoniazid, pyrazinamide and rifampicin), and the patient evol...
Authors: Salazar-Mejía CE, Wimer-Castillo BO PMID: 31326096 [PubMed - as supplied by publisher]
Authors: Krishnan M, N B, K T, S S PMID: 31324093 [PubMed - in process]
Condition: Carcinoma, Renal Cell Interventions: Drug: Spartalizumab; Drug: Canakinumab Sponsors: Charles G. Drake; Novartis Recruiting
Condition: Small Cell Lung Carcinoma Interventions: Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide Sponsor: Hoffmann-La Roche Not yet recruiting
Conditions: Carcinoma, Hepatocellular; Body Weight Interventions: Other: low dose CT contrast media - lean body weight; Other: Standard dose CT contrast media Sponsors: Seoul National University Hospital; Siemens Healthineers Recruiting
Conditions: Radiotherapy Side Effect; Chemotherapy Effect; Oesophageal Carcinoma; Effect of Drugs; Safety Issues Interventions: Combination Product: Neoadjuvant chemoradiotherapy; Procedure: Oesophagectomy; Drug: Neoadjuvant chemotherapy Sponsors: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Guangdong Provincial People's Hospital; Massachusetts General Hospital Completed